News AstraZeneca PLC

Equities

AZN

GB0009895292

Market Closed - London S.E. Other stock markets 11:35:08 2024-06-17 am EDT			5-day change	1st Jan Change
12,428 ^GBX	-0.66%		-1.37%	+17.25%

08:39am	AstraZeneca's Advanced Breast Cancer Drug Fails to Meet Primary Goals	DJ
Jun. 17	European Equities Close Mixed in Monday Trading; UBS Sued by Russian-Uzbek Billionaire Usmanov	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

AstraZeneca's Advanced Breast Cancer Drug Fails to Meet Primary Goals	02:39am	DJ
AstraZeneca : Update on CAPItello-290 Phase III trial	02:05am	PU
European Equities Close Mixed in Monday Trading; UBS Sued by Russian-Uzbek Billionaire Usmanov	Jun. 17	MT
Astrazeneca - Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial	Jun. 17	AQ
Global markets live: AstraZeneca, Apple, Meta, Microsoft, Cisco...	Jun. 17
AstraZeneca Says FDA Approves Imfinzi to Treat Endometrial Cancer	Jun. 17	MT
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer	Jun. 17	BU
AstraZeneca : Imfinzi plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer Form 6 K	Jun. 17	PU
AstraZeneca: positive phase 3 results in lymphoma	Jun. 17	CF
AstraZeneca's Blood Cancer Combination Therapy Meets Primary Goal in Late-Stage Study	Jun. 17	MT
London stocks rebound ahead of key Economic data	Jun. 17
Astra's Imfinzi plus chemo approved for cancer form in US	Jun. 17	AN
AstraZeneca: Imfinzi approved in endometrial cancer	Jun. 17	CF
Astra gets US drug approval; Ascential trades in line	Jun. 17	AN
AstraZeneca Gains US FDA Approval for Endometrial Cancer Treatment	Jun. 17	MT
UK Stocks-Factors to watch on June 17	Jun. 17	RE
AstraZeneca's Imfinzi Immunotherapy Gets U.S. FDA Approval for Endometrial Cancer	Jun. 17	DJ
AstraZeneca gets positive cancer test results for Calquence	Jun. 17	AN
AstraZeneca's Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer	Jun. 17	RE
AstraZeneca : Imfinzi approved in the US for endometrial cancer	Jun. 17	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT